Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.42 |
| ▸ | FABP7 | O15540 | 2/20 | 0.42 |
| ▸ | TLR2 | O60603 | 3/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29203790 | 1.00 | KMT2A (0.45) | KMT2AFABP5FABP7TLR2PPARG | |
| SCHEMBL29203732 | 1.00 | KMT2A (0.45) | KMT2AFABP5FABP7TLR2PPARG | |
| SCHEMBL415413 | 1.00 | KMT2A (0.45) | KMT2AFABP5FABP7TLR2PPARG | |
| SCHEMBL570371 | 0.93 | KMT2A (0.49) | KMT2AFABP5FABP7TLR2PPARG | |
| SCHEMBL14717015 | 0.87 | PPARG (0.46) | KMT2AFABP5FABP7TLR2PPARG | |
| SCHEMBL18528956 | 0.84 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL2316716 | 0.84 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL16011495 | 0.84 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL989369 | 0.84 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL15878722 | 0.84 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713348-A1 | DOUBLY CONSTRAINED PEPTIDES AS ALLOSTERIC INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | University of Georgia Research Foundation, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12565520-B2 | Chemically-stabilized allosteric modulators of leucine-rich repeat kinase 2 (LRRK2) | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-20250115546-A1 | LINKERS FOR ANTIBODY DRUG CONJUGATES | UNIV TEXAS (US) | 2025-04-10 | — | — | US | disclosed |
| US-12187816-B2 | Macrocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4467153-A1 | CONSTRAINED PEPTIDE INHIBITORS OF LRRK2-FADD INTERACTIONS | University of Georgia Research Foundation, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| WO-2024238623-A1 | DOUBLY CONSTRAINED PEPTIDES AS ALLOSTERIC INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| CN-111065623-B9 | Linker for antibody drug conjugates | 德克萨斯州大学系统董事会 | 2024-10-25 | — | — | CN | disclosed |
| CN-118652192-A | Linker for antibody drug conjugates | 德克萨斯州大学系统董事会 | 2024-09-17 | — | — | CN | disclosed |
| US-12084403-B2 | Linkers for antibody drug conjugates | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-09-10 | — | — | US | disclosed |
| US-20200115326-A1 | LINKERS FOR ANTIBODY DRUG CONJUGATES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2020-04-16 | — | — | US | disclosed |
| EP-3630189-A1 | LINKERS FOR ANTIBODY DRUG CONJUGATES | The Board of Regents of The University of Texas System (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10588935-B2 | FC receptor (FcRn) binding peptides and uses thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190183964-A1 | FC RECEPTOR (FcRn) BINDING PEPTIDES AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2019-06-20 | — | — | US | disclosed |
| WO-2018218004-A1 | LINKERS FOR ANTIBODY DRUG CONJUGATES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-11-29 | — | — | WO | disclosed |
| US-20180072782-A1 | DISRUPTION OF THE WAVE3 PROTEIN COMPLEX FOR SUPPRESSION OF INVASION AND METASTASIS | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20170209529-A1 | FC RECEPTOR (FcRn) BINDING PEPTIDES AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| US-9527890-B2 | FC receptor (FcRn) binding peptides and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-27 | — | — | US | disclosed |
| US-20160122394-A1 | FC RECEPTOR (FcRn) BINDING PEPTIDES AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-05-05 | — | — | US | disclosed |
| WO-2015192052-A1 | EGFR TARGETING COMPOUNDS AND METHODS OF USE THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187816-B2 | Macrocyclic compounds and methods of use thereof | PAICS, CYCS, LSS | KMT2A 2834/4885FABP5 4000/4885FABP7 2688/4885 |
| US-20250115546-A1 | LINKERS FOR ANTIBODY DRUG CONJUGATES | CD47, EPCAM, SDCBP | KMT2A 1971/4885FABP5 1135/4885FABP7 864/4885 |
| US-12084403-B2 | Linkers for antibody drug conjugates | CD47, EPCAM, SDCBP | KMT2A 1971/4885FABP5 1135/4885FABP7 864/4885 |
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | KMT2A 2834/4885FABP5 4000/4885FABP7 2688/4885 |
| US-12565520-B2 | Chemically-stabilized allosteric modulators of leucine-rich repeat kinase 2 (LRRK2) | LRRK2, SNCA, PARK7 | KMT2A 435/4885FABP5 3482/4885FABP7 2365/4885 |
| US-20200115326-A1 | LINKERS FOR ANTIBODY DRUG CONJUGATES | CD47, EPCAM, FCGRT | KMT2A 2311/4885FABP5 1053/4885FABP7 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.